Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition (updated)

Gossamer Bio

06/05/2024 13:17

(Adds background in paragraphs 2 and 3)
       May 6 (Reuters) - Gossamer Bio  GOSS.O  said on Monday
it will collaborate with Italian drugmaker Chiesi Group to
develop and commercialize its therapy seralutinib in multiple
indications related to high blood pressure due to constriction
of lung arteries.
    The therapy is currently in late-stage development for the
treatment of pulmonary arterial hypertension (PAH), which
affects about 40,000 people in the United States.
        While the company has not yet applied for approval from
the U.S. Food and Drug Administration, a potential nod could
make seralutinib a rival to Merck's  MRK.N  Winrevair, which 
    secured
     the agency's clearance for PAH in March.
  
    Gossamer is to receive $160 million in development
reimbursement payment and is eligible to receive up to $146
million in regulatory and $180 million in sales milestones as
part of the deal.

 (Reporting by Christy Santhosh; Editing by Vijay Kishore)
 ((Christy.Santhosh@thomsonreuters.com;))